Enanta Pharmaceuticals, Inc.'s (ENTA) CEO Jay Luly on Q2 2021 Results - Earnings Call Transcript

SA Transcripts
153.96K Followers

Q2: 2021-05-06 Earnings Summary

EPS of -$1.09 misses by $0.12
 | Revenue of $20.13M (-27.11% Y/Y) misses by $4.24M

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2021 Earnings Conference Call May 6, 2021 4:30 PM ET

Company Participants

Jennifer Viera - Investor Relations
Jay Luly - President and Chief Executive Officer
Paul Mellett - Chief Financial Officer
Nathalie Adda - Chief Medical Officer

Conference Call Participants

Brian Abrahams - RBC Capital Markets
Yasmeen Rahimi - Piper Sandler
Eric Joseph - J.P. Morgan
Roy Buchanan - JMP Securities LLC
Brian Skorney - Robert W. Baird & Co.
William Lee - Wolfe Research, LLC
Zegbeh Jallah - ROTH Capital Partners, LLC

Operator

Good afternoon and welcome to Enanta Pharmaceuticals Fiscal Second Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end of your prepared remarks. Please be advised that this call is being recorded.

I would now like to turn the call over to Jennifer Viera, Investor Relations. Please go ahead.

Jennifer Viera

Thank you, operator, and thanks to everyone for joining us this afternoon. The news release with our fiscal second quarter financial results was issued this afternoon and is available on our website.

On the call today is Dr. Jay Luly, President and Chief Executive Officer; Paul Mellett, our Chief Financial Officer; and other members of Enanta's senior management team.

Before we begin with our formal remarks, we want to remind you that we will be making forward-looking statements, which may include our plans and expectations with respect to our research and development pipeline and financial projections, all of which involve certain assumptions and risks beyond our control that could cause our actual developments and results to differ materially from those statements.

A description of these risks is in our most recent Form 10-Q and other periodic reports filed with the SEC. Enanta does not undertake any

Recommended For You

About ENTA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ENTA